Categories
Change Password!
Reset Password!
Experts from ECTS,
ASBMR, AACE, and NOF have issued guidelines regarding the management of
osteoporosis during COVID-19 pandemic.
A league of experts from the Endocrine Society, European
Calcified Tissue Society (ECTS), American Society for Bone and Mineral Research
(ASBMR), American Association of Clinical Endocrinologists (AACE), and National
Osteoporosis Foundation (NOF) formed a joint guidance statement about the
management of osteoporosis during the coronavirus disease 2019 pandemic.
As the need of the hour is primarily social distancing which
could possibly obstruct the osteoporosis treatment, therefore, the experts
proposed that the physicians should keep the following points in mind:
- Denosumab, they
should be provisionally transitioned to oral bisphosphonates if the time
from last injection surpasses 7 months (ie, a 1-month delay). Patients with
underlying gastrointestinal disorders can benefit from ibandronate (monthly
dose) and risedronate (weekly/monthly dose). Patients with chronic renal
insufficiency can benefit from oral bisphosphonates (low-dose)
- Romosozumab, Teriparatide or Abaloparatide, consider
a treatment delay. If
this delay exceeds 2 to 3 months, switch to oral bisphosphonates provisionally.
- IV bisphosphonates, consider a treatment delay. This delay for months is doubtfully harmful.
As the
magnitude of the COVID-19 is exceptional, these guidelines may help the
healthcare professionals to adjust treatment for patients to oral
bisphosphonates helpful both for the physicians and their patients.
https://www.empr.com/home/news/expert-guidance-for-osteoporosis-management-during-covid-19-pandemic/
Societies Issue Joint Guidance for Osteoporosis Management During the COVID-19 Pandemic
Comments (0)